---
title: "Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Place in treatment, anticipated use, and care setting"
description: "Formulary evidence on Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Place in treatment, anticipated use, and care setting. Topics: Summary: studied population and anticipated use, Summary: care setting, Sponsor statement: absence of disease-modifying therapy and limits of symptomatic treatment, Sponsor target profile: one-time administration into the striatum, and 9 further topics. 13 evidence topics quoted from 11 sources."
canonical: "https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/product-information-and-disease-description/place-in-treatment-anticipated-use-and-care-setting"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Place in treatment, anticipated use, and care setting

<a id="heading-2.2.2.2"></a>

## 2.2.2.2 Place in Treatment, Anticipated Use, and Care Setting

<a id="topic-2.2.2.2-1"></a>

### Summary: studied population and anticipated use

- Studied population: the U.S. Phase I/II study and the European Phase Ib/II study use the same early manifest criteria, enrolling males and females aged 25 to 65 years with a definitive clinical diagnosis of early manifest HD and a CAG repeat of ≥40. Key eligibility criteria in one presentation included a total functional capacity of 9-13, a diagnostic confidence level of 3 or 4, HD medications stable for the prior 3 months, and striatal volumes exceeding specified minima (putamen ≥ 2.5 cm3/side; caudate ≥ 2.0 cm3/side).
- Anticipated use: the sponsor states that no available therapy can delay onset or slow progression, and that available symptomatic treatments are only transiently effective and often associated with significant side effects. The sponsor's target profile is a one-time administration of a disease-modifying therapy into the striatum. ICER's assessment names usual symptomatic care (treatment for movement disorders, psychiatric and mood symptoms, physical therapy) as the comparator. A public comment asked ICER to incorporate HD staging (ISS-2 and ISS-3) into the scope, and authors of the HD Integrated Staging System state that it could facilitate trials in populations before clinical motor diagnosis.

Source: [uniQure Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1590560/000110465926021898/qure-20251231x10k.htm); [uniQure Phase I/II clinical trial page](https://www.uniqure.com/programs-pipeline/phase-1-2-clinical-trial-of-amt-130); [Margolin et al. (2026)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/CHDI-2026Feb-AMT-130-striatal-volumes-FINAL-PDF.pdf); [ICER revised scope (2026)](https://icer.org/wp-content/uploads/2026/09/ICER_Huntingtons-Disease_Revised-Scope_For-Publication_092126.pdf); [ICER public comments on draft scope (2026)](https://icer.org/wp-content/uploads/2026/09/ICER_Huntingtons-Disease_Folio_092126.pdf); [Tabrizi et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35716693/)

<a id="topic-2.2.2.2-2"></a>

### Summary: care setting

- Administration: in the Phase I/II studies, each treated patient received a single administration through MRI-guided, convection-enhanced stereotactic neurosurgical delivery directly into the striatum (caudate and putamen).
- Access to specialty care: clinical experts told ICER that about 30% of patients with HD receive specialty care with a movement disorders neurologist, and half of those receive care at an HD Center of Excellence, which raises concern about access to new treatments offered only at specialty centers. A public comment to ICER stated that access is limited to a few neurosurgical centers, that effects beyond four years are unknown, and that there are no retreatment data.
- Centers of Excellence: there are 60 HDSA Centers of Excellence and 9 Partner Sites covering 37 States plus the District of Columbia, each providing a multidisciplinary team approach. HDSA's comment to ICER states that these centers can inform the treatment burden, access barriers, caregiver requirements, travel, follow-up, and infrastructure needed to deliver a new therapy.
- Payer analog: Aetna's criteria for eladocagene exuparvovec-tneq (Kebilidi) require precertification, prescription by or in consultation with a neurologist, geneticist, or physician specializing in inherited metabolic diseases, and administration in a medical center that specializes in stereotactic neurosurgery; the policy states that gene and cellular therapies must be administered at an Aetna GCIT Network unless the member's plan has elected otherwise.

Source: [uniQure press release, statistical analysis plan and CMC alignment (2025)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-provides-regulatory-update-amt-130-huntingtons-disease); [ICER revised scope (2026)](https://icer.org/wp-content/uploads/2026/09/ICER_Huntingtons-Disease_Revised-Scope_For-Publication_092126.pdf); [ICER public comments on draft scope (2026)](https://icer.org/wp-content/uploads/2026/09/ICER_Huntingtons-Disease_Folio_092126.pdf); [Huntington's Disease Society of America Centers of Excellence](https://hdsa.org/find-help/clinical-care-services/hdsa-centers-of-excellence/); [Aetna clinical policy bulletin 1073 (2026)](https://www.aetna.com/cpb/medical/data/1000_1099/1073.html)

<a id="topic-2.2.2.2-3"></a>

### Sponsor statement: absence of disease-modifying therapy and limits of symptomatic treatment

> “There is currently no available therapy that can delay onset or slow progression of the disease. Although some symptomatic treatments are available, they are only transiently effective and are often associated with significant side effects.”

Source: [uniQure Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1590560/000110465926021898/qure-20251231x10k.htm)

<a id="topic-2.2.2.2-4"></a>

### Sponsor target profile: one-time administration into the striatum

> “Our goal for AMT-130 is to develop a gene therapy with the following profile:”
> “one-time administration of a disease-modifying therapy into the striatum, the area of the brain where Huntington’s disease is known to manifest;”

Source: [uniQure Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1590560/000110465926021898/qure-20251231x10k.htm)

<a id="topic-2.2.2.2-5"></a>

### Comparator care in the ICER assessment: usual symptomatic care

> “Usual symptomatic care (treatment for movement disorders [e.g., chorea], psychiatric and mood symptoms, physical therapy, etc.)”

Source: [ICER revised scope (2026)](https://icer.org/wp-content/uploads/2026/09/ICER_Huntingtons-Disease_Revised-Scope_For-Publication_092126.pdf)

<a id="topic-2.2.2.2-6"></a>

### Access to specialty neurology care: clinical expert input to ICER

> “Clinical experts relayed that only about 30% of patients with HD get specialty care with a movement disorders neurologist, and only half of those patients get care at an HD Center of Excellence.”
> “This difficulty in accessing specialized neurology care results both in a long journey to diagnosis and concerns about patients’ ability to access new treatments that may only be offered at specialty centers.”

Source: [ICER revised scope (2026)](https://icer.org/wp-content/uploads/2026/09/ICER_Huntingtons-Disease_Revised-Scope_For-Publication_092126.pdf)

<a id="topic-2.2.2.2-7"></a>

### HDSA Centers of Excellence and delivery of a new therapy: HDSA comment to ICER

> “HDSA also recommends that ICER engage directly with HDSA Centers of Excellence (COEs) as an important source of patient-centered expertise.”
> “COEs can also provide insight into the practical implications of a new therapy, including treatment burden, access barriers, caregiver requirements, travel, follow-up, and the infrastructure necessary to deliver specialized care.”

Source: [ICER public comments on draft scope (2026)](https://icer.org/wp-content/uploads/2026/09/ICER_Huntingtons-Disease_Folio_092126.pdf)

<a id="topic-2.2.2.2-8"></a>

### Neurosurgical center access, retreatment, and disease stage: public comment to ICER on the draft scope

> “These challenges are even greater here because effects beyond four years are unknown, access is limited to a few neurosurgical centers (creating geographic inequities), and there is no retreatment data.”
> “ICER should explicitly incorporate HD staging (e.g., ISS-2 and ISS-3) into the AMT-130 scope and align outcome measures to stage-specific treatment goals.”

Source: [ICER public comments on draft scope (2026)](https://icer.org/wp-content/uploads/2026/09/ICER_Huntingtons-Disease_Folio_092126.pdf)

<a id="topic-2.2.2.2-9"></a>

### Care setting analog: Aetna criteria for the gene therapy Kebilidi, administered at a stereotactic neurosurgery center

> “Note: Unless member's health plan has elected not to require, gene and cellular therapies must be administered at an Aetna Institutes® Gene Based, Cellular and Other Innovative Therapy (GCIT®) Network.”
> “Precertification of eladocagene exuparvovec-tneq (Kebilidi) is required of all Aetna participating providers and members in applicable plan designs.”
> “This medication must be prescribed by or in consultation with a neurologist, geneticist, or physician specializing in the treatment of inherited metabolic diseases.”
> “Kebilidi will be administered in a medical center which specializes in stereotactic neurosurgery; and”

Source: [Aetna clinical policy bulletin 1073 (2026)](https://www.aetna.com/cpb/medical/data/1000_1099/1073.html)

<a id="topic-2.2.2.2-10"></a>

### Target stages: HD Integrated Staging System

> “These initial stages, which have only recently become a focus of study, are particularly promising as they may reveal the most effective targets for disease-modifying therapies.”

Source: [Sampaio et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11307057/)

<a id="topic-2.2.2.2-11"></a>

### HD-ISS as a framework for earlier intervention

> “The adoption of the HD-ISS could facilitate the design of clinical trials targeting populations before clinical motor diagnosis and enable data standardisation across ongoing and future studies.”

Source: [Tabrizi et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35716693/)

<a id="topic-2.2.2.2-12"></a>

### Care setting: MRI-guided neurosurgical administration of AMT-130

> “Treated patients received a single administration of AMT-130 through MRI-guided, convection-enhanced stereotactic neurosurgical delivery directly into the striatum (caudate and putamen).”

Source: [uniQure press release, statistical analysis plan and CMC alignment (2025)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-provides-regulatory-update-amt-130-huntingtons-disease)

<a id="topic-2.2.2.2-13"></a>

### Specialist care setting: HDSA Centers of Excellence

> “HDSA Centers of Excellence provide a multidisciplinary team approach to Huntington’s disease care.”
> “There are currently 60 HDSA Centers of Excellence and 9 Partner Sites covering 37 States plus the District of Columbia.”

Source: [Huntington's Disease Society of America Centers of Excellence](https://hdsa.org/find-help/clinical-care-services/hdsa-centers-of-excellence/)

Additional sources: [Willock et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/38108355/)

## Related pages
- [Ifezuntirgene inilparvovec (AMT-130): Huntington's disease](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Terms and abbreviations](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/terms-and-abbreviations.md)
- [Ifezuntirgene inilparvovec (AMT-130): Huntington's disease](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/executive-summary.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Product information and disease description](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/product-information-and-disease-description.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Clinical evidence](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/clinical-evidence.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Economic information and modeling report](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/economics) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/economics.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: References](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/references) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/references.md)
